JAZZ PHARMACEUTICALS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 111.2 USD | +1.24% |
|
+0.42% | -9.59% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 4.05B | Sales 2025 * | 4.36B | Capitalization | 6.92B |
|---|---|---|---|---|---|
| Net income 2024 * | 430M | Net income 2025 * | 619M | EV / Sales 2024 * | 2.58 x |
| Net Debt 2024 * | 3.55B | Net Debt 2025 * | 2.05B | EV / Sales 2025 * | 2.06 x |
| P/E ratio 2024 * |
18.7
x | P/E ratio 2025 * |
12.1
x | Employees | 2,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on Jazz Pharmaceuticals plc
More recommendations
More press releases
| 1 day | +1.24% | ||
| 1 week | +0.42% | ||
| Current month | +0.42% | ||
| 1 month | -4.48% | ||
| 3 months | -9.54% | ||
| 6 months | -16.80% | ||
| Current year | -9.59% |
1 week
103.01
113.36
1 month
103.01115.94
Current year
103.01134.17
1 year
103.01146.70
3 years
103.01189.00
5 years
86.88189.00
10 years
86.88194.73
| Managers | Title | Age | Since |
|---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 19.34% | 13 M€ | -.--% | ||
| 14.47% | 0 M€ | +10.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 111.2 | +1.24% | 841,956 |
| 24-05-06 | 109.8 | -0.15% | 571,216 |
| 24-05-03 | 110 | +0.66% | 693,769 |
| 24-05-02 | 109.3 | -0.92% | 1,061,749 |
| 24-05-01 | 110.3 | -0.40% | 800,753 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
Pharmaceuticals
Calendar
2024-05-15
- BofA Securities Health Care Conference
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
111.2
USD
Average target price
182
USD
Spread / Average Target
+63.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.59% | 6.92B | |
| +33.43% | 690B | |
| +26.43% | 546B | |
| -5.12% | 358B | |
| +19.59% | 323B | |
| +4.89% | 287B | |
| +14.32% | 235B | |
| +5.79% | 199B | |
| -9.49% | 195B | |
| +4.26% | 161B |
- Stock Market
- Equities
- JAZZ Stock